Calliditas Therapeutics AB (CALT): מכפיל EV/EBITDA

Calliditas Therapeutics (CALT) maintains its leadership in the niche segment of rare kidney disease therapy, leveraging the commercial advancement of Tarpeyo and the expansion of clinical trials. This chart on the GURU.Markets platform for the EV/EBITDA metric is . High barriers to entry are driven by massive R&D expenditures, stringent FDA oversight, and patent protection, which limit competition within the industry.

The business scalability of Calliditas Therapeutics (CALT) is reflected in the dynamics of the Enterprise Value to EBITDA multiple. This indicator compares the total value of the asset with its operating profit before depreciation and interest, eliminating distortions from debt load. For a company with efficiently utilized R&D laboratories and streamlined partner manufacturing, the calculation confirms the real value of the business relative to its ability to generate cash flow.